These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 21827214)

  • 1. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of tyrosine kinase inhibitors.
    van Erp NP; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Ding JF; Zhong DF
    Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
    Heine A; Schilling J; Grünwald B; Krüger A; Gevensleben H; Held SA; Garbi N; Kurts C; Brossart P; Knolle P; Diehl L; Höchst B
    Cancer Immunol Immunother; 2016 Mar; 65(3):273-82. PubMed ID: 26786874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
    Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
    Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
    Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
    Narjoz C; Favre A; McMullen J; Kiehl P; Montemurro M; Figg WD; Beaune P; de Waziers I; Rochat B
    PLoS One; 2014; 9(5):e95532. PubMed ID: 24819355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
    Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
    Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
    Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
    Tullemans BME; Veninga A; Fernandez DI; Aarts MJB; Eble JA; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
    J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors.
    Trent J; Molimard M
    Semin Oncol; 2011 Apr; 38 Suppl 1():S28-33. PubMed ID: 21419933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Andriamanana I; Gana I; Duretz B; Hulin A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.